IRCT20090822002365N23 IRCT 2019-08-16 National Institute for Medical Research Development Effect of vitamin D & magnesium on inflammation and obesity- induced depressive symptoms Effect of vitamin D and/or magnesium supplementation on mood, serum level of BDNF, inflammation, and SIRT1 in obese women 2019-09-06 anticipated 80 Complete https://irct.ir/trial/41246 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Factorial, Purpose: Treatment, Randomization description: For randomized allocation performing, permuted block randomization will be used by quadrilateral blocks. According to the sample size of 80 subjects, 20 blocks will be generated using the online site (www.sealedenvelope.com). In order to allocation concealment in the randomized process, unique codes will be used on the drug boxes that is generated by the software. Participants will be entered into study based on the produced sequence. The drug packets will be allocated to the individual with code on them. Therefore, participants will be unaware of the type of intervention that will receive, as well as the random sequence which will be hidden and unpredictable, Blinding description: For blinding, a person who will not be involved in study protocol will create the randomization list assigning participants to the vitamin D, magnesium, co-supplementation or the placebo group. Vitamin D, magnesium, and placebo tablets will be placed into identical containers which study manager will label them with participant numbers using the randomization list. All investigators, and participants will be blinded to the random assignments. 3 Obesity. Intervention 1: Intervention group 1: a 50000 IU vitamin D tablet (Zahravi, Iran), weekly+ a magnesium tablet (each tablet containing 250 mg magnesium in the form of magnesium oxide) (Jalinous, Iran), daily, for 8 weeks. Intervention 2: Intervention group 2: a 50000 IU vitamin D tablet (Zahravi, Iran), weekly a magnesium placebo (Zahravi, Iran), daily, for 8 weeks. Intervention 3: Intervention group 3: a magnesium tablet (each tablet containing 250 mg magnesium in the form of magnesium oxide) (Jalinous, Iran), daily+ a vitamin D placebo (Zahravi, Iran), weekly, for 8 weeks. Intervention 4: Control group: a vitamin D placebo (Zahravi, Iran), weekly+ a magnesium placebo (Zahravi, Iran), daily, for 8 weeks. Yes - There is a plan to make this available What will be shared: A part of the data will be shared, such as primary outcomes. When: Four months after the publication of the results. To whom: Researchers and students of university. Conditions: Four months after the publication of this study papers, the obtained data will be available to the applicant researchers and students for further analysis. Where to obtain: Applicants can be contacted with corresponding author by e-mail or postal address to receive the requested data. Postal address: Nutrition Department, School of health, Iran University of Medical Science, Hemmat Expressway, Tehran Phone Number: 0098 2186704743 E-mail: rezavafa@yahoo.com How to obtain: Applicants can be contacted with corresponding author by e-mail or postal address to receive the requested data. Postal address: Nutrition Department, School of health, Iran University of Medical Science, Hemmat Expressway, Tehran Phone Number: 0098 2186704743 E-mail: rezavafa@yahoo.com Comments: